循环肿瘤DNA预测HPV阳性口咽癌复发:一项Meta分析
本Meta分析纳入20项研究、3505例临床相关检测,评估血清ctDNA对HPV阳性口咽鳞癌根治后复发的监测价值。汇总敏感度80.3%、特异度95.5%,复发率9.70%时阴性预测值97.7%、阳性预测值66.0%,ctDNA阳性者复发风险显著升高。ctDNA是有前景的复发早期检测标志物,但需标准化方案与定量阈值。
要点
- 血清ctDNA监测HPV阳性口咽癌根治后复发,汇总敏感度80.3%、特异度95.5%。
- 复发率9.70%背景下,ctDNA阴性预测值97.7%,阳性预测值66.0%。
- ctDNA阳性者复发风险显著升高,但临床推广需标准化检测方案与阈值。
核心结论
- ctDNA是HPV阳性口咽癌根治后复发早期检测的有前景标志物。
- 需标准化检测方案与定量阈值以确立其临床作用。
研究设计与样本
- 系统综述与Meta分析,遵循PRISMA,检索PubMed。
- 初检419篇,最终纳入20项符合标准的研究。
- 采用牛津循证医学中心与纽卡斯尔-渥太华量表进行质量评价。
主要发现
- 汇总3505例临床相关检测,ctDNA敏感度80.3%(95%CI 70.9%-87.2%),特异度95.5%(95%CI 90.9%-97.8%)。
- 根治后复发HPV阳性口咽癌总体患病率9.70%(95%CI 8.72%-10.78%)。
- 该患病率下阴性预测值97.7%(95%CI 96.7%-98.5%),阳性预测值66.0%(95%CI 49.5%-80.3%)。
- ctDNA阳性者复发 odds 比阴性者高130.3倍(95%CI 56.60-298.71)。
关键数值与推荐
- 纳入标准:提供治疗前后HPV病毒载量数据,聚焦HPV阳性口咽癌。
- 排除标准:其他解剖部位HPV相关癌、缺乏治疗前后病毒载量数据、发表超过20年。
临床怎么用
- 可将血清ctDNA作为HPV阳性口咽癌根治后复发监测的候选标志物。
- 阴性结果对排除复发有较高价值,阳性结果需结合影像或病理确认。
局限性
- 需标准化检测方案与定量阈值后方可常规用于临床决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To perform a systematic review and meta-analysis on the utility of circulating tumor DNA (ctDNA) in serum as a biomarker for post-treatment surveillance of human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma (OPSCC), given the improved treatment response and 10% to 20% recurrence rate in this patient population. DATA SOURCES: Articles were sourced from PubMed. Studies were excluded if they focused on HPV-driven cancers in other anatomical regions, lacked pretreatment and posttreatment HPV viral load data, or were published more than 20 years ago. All literature available in English was considered. REVIEW METHODS: A PRISMA-compliant review identified 419 articles, and 20 studies met all inclusion criteria. Data extraction and quality assessment were performed using Oxford Centre for Evidence-Based Medicine and Newcastle-Ottawa Scale criteria. RESULTS: Across 3505 clinically correlated tests, pooled sensitivity was 80.3% (95% CI 70.9%-87.2%) and specificity was 95.5% (90.9%-97.8%). Meta-analysis of our studies found the overall prevalence of recurrent HPV + OPSCC after curative treatment was 9.70% (95% CI 8.72%-10.78%). Negative Predictive Value (NPV) at this prevalence was 97.7% (96.7%-98.5%) and Positive Predictive Value (PPV) was 66.0% (49.5%-80.3%). A positive test for ctDNA after curative treatment had a 130.3 (95% CI 56.60-298.71) fold higher odds of disease recurrence compared to a negative test. CONCLUSIONS: CtDNA is a promising biomarker for early detection of recurrence. Standardized protocols and quantitative thresholds are needed to fully establish its role in clinical practice.
引用
- Sturek C, Carr S, Thornton A, et al. Recurrence and Circulating Tumor DNA in Human Papillomavirus-Positive Oropharyngeal Cancer: A Meta-Analysis. Otolaryngol Head Neck Surg. 2026. PMID: 42726930. doi:10.1002/ohn.70426
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。